Recent News

• 02.26.2025 - Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
• 02.18.2025 - Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
• 02.11.2025 - Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
• 02.06.2025 - Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
• 02.06.2025 - Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
• 01.28.2025 - Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
• 01.21.2025 - Kairos Pharma Provides Business Update and Outlook into 2025
• 01.21.2025 - Kairos Pharma Provides Business Update and Outlook into 2025

Recent Filings

• 02.26.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - DEF 14C Other definitive information statements
• 02.06.2025 - EX-99.1 EX-99.1
• 02.06.2025 - 8-K Current report
• 02.05.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.04.2025 - EFFECT Notice of Effectiveness
• 01.29.2025 - S-1 General form for registration of securities under the Securities Act of 1933